Abcon Therapeutics, Inc.
Categories
PharmaceuticalsDescription
Abcon Therapeutics is developing an antibody-drug conjugate (ADC) that targets the CD6 cell surface protein on T-cells. In pathogenic conditions, such as T-cell lymphoma and inflammatory conditions, the ADC binds to all T-cells, but the drug (toxin) only affects activated dividing T-cells (i.e. the cancerous ones in T-Cell Lymphoma) so these are killed, and normal inactive T-cells are spared. CD6 is found exclusively on T-cells; thus, the ADC specificity is very good. The Company plans to develop a pipeline of ADCs targeting different types of cancer.
Business Overview
Directions to listing
Disclaimer
The Ohio Life Sciences Directory is provided by Ohio Life Sciences for the purpose of promoting life sciences-related organizations in Ohio. Profiles are based on publicly available and company-provided information. Ohio Life Sciences is a member supported organization, therefore members are prioritized in search results and receive special logo visibility, but non-members are included. Members may request a targeted, staff-generated offline search of the Directory. Ohio Life Sciences works to keep the Directory up to date, however, as details may change without notice, users should always refer to the listed organization directly for current information. Placement of a Directory listing does not represent an endorsement or testimony from Ohio Life Sciences as to the quality/validity of the products/services listed. Ohio Life Sciences retains exclusive management of OhioLifeSciences.org content and reserves the right to accept, reject, or remove listings on the Ohio Life Sciences website at any time. Questions? Want to update or list your organization? Please visit our contact page.